Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 9Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1

Interventions

venetoclax 27Cyclophosphamide 18Azacitidine 13fludarabine 12ibrutinib 10Busulfan 10fludarabine phosphate 9Rituximab 8Mycophenolic Acid 8Methotrexate 8Cytarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Clofarabine 7Therapeutics 6Melphalan 6Antilymphocyte Serum 6obinutuzumab 5Tacrolimus 5Surveys and Questionnaires 5Stem Cell Transplantation 5Mesna 5Exercise 5Cyclosporine 5vosaroxin 4trametinib 4thymoglobulin 4ruxolitinib 4ponatinib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × BI 6727 × Other hematologic neoplasm × Clear all
NCT01971476 2018-07-30

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Boehringer Ingelheim

Phase 1 Completed
22 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡